Strategic partnerships Aeterna Zentaris leverages licensing agreements for Macrilen in the U.S. and is seeking European and global commercialization opportunities, presenting a clear pathway for BD teams to target regional licensees, distributors, and co-development partners to expand market access.

Growth hormone diagnostics Macrilen is the first oral diagnostic test approved for AGHD, with ongoing exploration for CGHD; sales opportunities exist with endocrinology clinics, hospital networks, and diagnostic labs seeking reliable, convenient testing solutions.

Global expansion Active pursuit of Europe and rest-of-world commercialization suggests potential for partnerships with regional pharma distributors, payers, and health systems to secure reimbursement and market access for macimorelin outside North America.

Digital and data Tech stack use including Google Cloud and analytics indicates potential for data-driven sales approaches, digital marketing co-ops, and remote engagement strategies with healthcare providers to accelerate adoption and evidence generation.

Financially lean Revenue range and a small employee base imply a nimble organization open to strategic collaborations, co-promotion, and asset monetization deals that minimize overhead while maximizing global reach for macimorelin and related assets.